Business Context and Reporting Period
Company: Stryker Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2001
Business Overview: Stryker develops, manufactures, and markets specialty surgical and medical products, including orthopaedic implants (hip, knee, shoulder, trauma, spinal), powered surgical instruments, endoscopic systems, and patient care equipment. The company also provides outpatient physical and occupational rehabilitative services in the United States. Operations are segregated into two reportable segments: Orthopaedic Implants and MedSurg Equipment.
Key Financial Metrics
| Metric ($ millions) | 2001 | 2000 | Change |
|---|---|---|---|
| Net Sales | $2,602.3 | $2,289.4 | +14% |
| Gross Profit | $1,638.5 | $1,474.2 | +11% |
| Gross Margin | 63.0% | 64.4% | -1.4 pts |
| Net Earnings | $267.0 | $221.0 | +21% |
| Diluted EPS | $1.32 | $1.10 | +20% |
| Operating Cash Flow | $468.3 | $331.8 | +41% |
| Total Debt (Long-term + Current) | $722.6 | $1,012.5 | -29% |
| Working Capital | $459.7 | $379.6 | +21% |
| Current Ratio | 1.9 | 1.6 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14% to $2.6 billion, driven by a 12% increase in unit volume/mix, 3% price increases, and 1% from acquisitions. This was partially offset by a 3% decline due to foreign currency exchange rates. Domestic sales grew 20%, while international sales grew 4% (11% excluding currency impact).
- Segment Performance: Orthopaedic Implants sales rose 10% to $1.44 billion. MedSurg Equipment sales increased 18% to $979 million. Physical Therapy Services revenue grew 23% to $181 million.
- Margin Compression: Gross margin decreased from 64.4% to 63.0%. This was primarily due to a change in accounting classification where freight revenue was recorded as net sales (rather than an offset to cost of sales) and shipping costs were moved from SG&A to Cost of Sales. Additionally, unabsorbed manufacturing costs increased due to production slowing to reduce inventory.
- Debt Reduction: Total debt declined by $289.9 million. In December 2001, the company refinanced and prepaid $642.7 million of its 1998 Senior Secured Credit Facilities, replacing them with $1.0 billion in Unsecured Credit Facilities. This resulted in an extraordinary loss of $4.8 million (net of tax) due to the write-off of unamortized deferred loan costs.
- Restructuring: The company recorded $0.6 million in acquisition-related and restructuring charges in 2001, compared to a $1.0 million credit in 2000.
Guidance, Outlook, and Risks
- OP-1 Implant: The company received Humanitarian Device Exemption (HDE) approval from the FDA in October 2001 for its OP-1 bone growth device for recalcitrant long bone nonunions. Commercial sales began in November 2001. The company cannot predict the future sales impact of this product.
- Accounting Changes: The adoption of FASB Statement No. 142 (Goodwill and Other Intangible Assets) is expected to reduce intangibles amortization by approximately $16 million and increase net earnings by approximately $11 million in 2002. Initial impairment tests for goodwill will be performed in Q1 2002.
- Insurance Costs: The company anticipates a substantial increase in insurance premiums in 2002 due to changed conditions in the insurance industry, which is expected to offset the $9 million interest expense savings from the debt refinancing.
- Market Risks: Significant exposure to foreign currency exchange rates (specifically the Euro and Japanese Yen). The company uses forward currency contracts and yen-denominated borrowings to hedge these risks. Interest rate risk is managed via swap agreements covering approximately 77% of variable-rate borrowings.
- Regulatory Risks: Ongoing regulatory actions and cost-containment measures by third-party payors could adversely affect product pricing and demand.
Investor Verification Checklist
- Debt Refinancing Impact: Verify the net benefit of the December 2001 refinancing after accounting for the $9 million interest savings versus the anticipated increase in insurance premiums.
- OP-1 Commercialization: Monitor early sales data for the OP-1 Implant under the HDE approval to assess its potential contribution to future revenue.
- Goodwill Impairment: Review the results of the initial goodwill impairment tests scheduled for Q1 2002 under FASB 142, which could result in a one-time charge.
- Foreign Currency Sensitivity: Assess the impact of a strengthening U.S. dollar on international sales, which accounted for 35% of total revenue in 2001.
- Inventory Management: Confirm that the reduction in days sales in inventory (from 166 to 138 days) is sustainable and not indicative of future demand weakness.